Shots:

• Tyme to receive $20M up front for 10M restricted shares of common stock at $2/share- up to $20M milestones based on meeting @1EPs as OS in TYME-88-Panc pivotal trial and PanCAN Precision Promise SM-88 registration arm plus US FDA approval of SM-88 in any cancer and will be split into $10M cash and rest investment at 15% premium
• Eagle to fund 25% of promotional sales efforts and will receive 15% revenue for SM-88 in the US. Tyme will retain 85% net US revenue plus rights to repurchase Eagle’s co-promotion right for $200M and will take care of clinical development- regulatory approval- commercial strategy- marketing- reimbursement manufacturing of SM-88
• The companies will also evaluate oral SM-88 in combination or monothx combining Eagle’s oncology pipeline + expertise in multiple cancer including breast or lung. SM-88 is an oral modified proprietary tyrosine derivative targeted to disrupt protein synthesis in cancer cells and is evaluated in P-III trial

Click here to read full press release/ article | Ref: GlobeNewswire | Image: Signbox